Natural killer cell expressing anti-cotinine chimeric antigen receptor

The present invention relates to a natural killer cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent comprising same. The natural killer cell expressing a chimeric antigen receptor specifically binding to cotinine, accordin...

Full description

Saved in:
Bibliographic Details
Main Authors LEE SOO-YUN, CHUNG JUN-HO, KIM TAE-DON, KIM KI-HYUN, CHOI IN-PYO, LEE SU-UI
Format Patent
LanguageChinese
English
Published 19.11.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a natural killer cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent comprising same. The natural killer cell expressing a chimeric antigen receptor specifically binding to cotinine, according to the present invention, can effectively move to tumor tissue, regardless of the kind of cancer,depending on the binding substance bound to cotinine. Therefore, the natural killer cell according to the present invention can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect. 本发明涉及表达特异性结合可替宁的抗可替宁嵌合抗原受体(CAR)的天然杀伤细胞,以及含有该细胞的细胞治疗剂。根据与可替宁偶联的结合物质,表达特异性结合可替宁的嵌合抗原受体的本发明天然杀伤细胞可以有效移动到肿瘤组织,而无论癌症的类型。因此,本发明的天然杀伤细胞可以有效地用作表现出高效抗癌作用的基因疗剂。
Bibliography:Application Number: CN201880006118